HK1213780A1 - 穩定的葡萄糖激酶活化劑組合物 - Google Patents

穩定的葡萄糖激酶活化劑組合物 Download PDF

Info

Publication number
HK1213780A1
HK1213780A1 HK16101756.4A HK16101756A HK1213780A1 HK 1213780 A1 HK1213780 A1 HK 1213780A1 HK 16101756 A HK16101756 A HK 16101756A HK 1213780 A1 HK1213780 A1 HK 1213780A1
Authority
HK
Hong Kong
Prior art keywords
cyclohexyl
nanoparticles
ylsulfanyl
ureido
thiazol
Prior art date
Application number
HK16101756.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧莫
Y‧莫
‧戴德希亞
M‧G‧戴德希亚
‧切特裡
A‧切特里
Original Assignee
Vtv治疗有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv治疗有限责任公司 filed Critical Vtv治疗有限责任公司
Publication of HK1213780A1 publication Critical patent/HK1213780A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16101756.4A 2013-03-04 2014-02-28 穩定的葡萄糖激酶活化劑組合物 HK1213780A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772022P 2013-03-04 2013-03-04
US61/772,022 2013-03-04
PCT/US2014/019349 WO2014137797A2 (en) 2013-03-04 2014-02-28 Stable glucokinase activator compositions

Publications (1)

Publication Number Publication Date
HK1213780A1 true HK1213780A1 (zh) 2016-07-15

Family

ID=50424705

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101756.4A HK1213780A1 (zh) 2013-03-04 2014-02-28 穩定的葡萄糖激酶活化劑組合物

Country Status (11)

Country Link
US (1) US20160015638A1 (cg-RX-API-DMAC7.html)
EP (1) EP2964198A2 (cg-RX-API-DMAC7.html)
JP (1) JP6441828B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150123838A (cg-RX-API-DMAC7.html)
CN (1) CN105050585A (cg-RX-API-DMAC7.html)
AU (1) AU2014226290B2 (cg-RX-API-DMAC7.html)
CA (1) CA2903433A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213780A1 (cg-RX-API-DMAC7.html)
IL (1) IL240735A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015011109A (cg-RX-API-DMAC7.html)
WO (1) WO2014137797A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603614A (en) 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
BR112014028622A2 (pt) 2012-05-17 2017-06-27 Transtech Pharma Llc composições de ativador de glucoquinase para o tratamento de diabetes
EP3556354B1 (en) * 2016-12-15 2025-05-21 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3185831A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CN121202809A (zh) * 2020-06-08 2025-12-26 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
CA3181722A1 (en) * 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
CA2488617A1 (en) * 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
EP1835890A2 (en) * 2005-01-06 2007-09-26 Elan Pharma International Limited Nanoparticulate candesartan formulations
JP2008531591A (ja) * 2005-02-24 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド ドセタキセルおよびそれらの類似体のナノ粒子製剤
MX2007011494A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
CN101262860A (zh) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
ES2335608T3 (es) * 2005-06-09 2010-03-30 Elan Pharma International Limited Formulaciones de ebistina nanoparticuladas.
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
BRPI0717721A2 (pt) * 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
US8163779B2 (en) * 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US20090028680A1 (en) * 2007-07-27 2009-01-29 Kling Troy L Intermediate apparatus for towing utility vehicles
KR20110018366A (ko) * 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
JP2010049784A (ja) * 2008-07-23 2010-03-04 Hitachi High-Technologies Corp 複合磁気ヘッドの書込／読出幅測定方法および測定装置
KR20120052937A (ko) * 2009-06-18 2012-05-24 아보트 러보러터리즈 안정한 나노입자형 약물 현탁액
EP2442794A1 (en) * 2009-06-19 2012-04-25 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
NZ603614A (en) * 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

Also Published As

Publication number Publication date
US20160015638A1 (en) 2016-01-21
JP6441828B2 (ja) 2018-12-19
WO2014137797A2 (en) 2014-09-12
CN105050585A (zh) 2015-11-11
KR20150123838A (ko) 2015-11-04
AU2014226290A1 (en) 2015-10-08
MX2015011109A (es) 2015-11-16
EP2964198A2 (en) 2016-01-13
AU2014226290B2 (en) 2018-11-15
WO2014137797A3 (en) 2014-10-30
CA2903433A1 (en) 2014-09-12
JP2016513625A (ja) 2016-05-16
IL240735A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
JP6441828B2 (ja) 安定なグルコキナーゼ活性化剤組成物
Gao et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs
US20230321246A1 (en) High-strength oral taxane compositions and methods
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
US20240207239A1 (en) Composition and preparation method therefor
CN105188676A (zh) 包括葡糖激酶活化剂的固体组合物及其制备和使用方法
CN105007897A (zh) 含有无定形托伐普坦的口服施用的混悬剂
WO2008077591A2 (en) Pharmaceutical formulation comprising neurokinin antagonist
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
US20200078463A1 (en) Composition having improved water solubility and bioavailability
EP3305282A2 (en) Composition of pranlukast-containing solid preparation with improved bioavailability and method for preparing same
CN121818963A (zh) 维拉佐酮包合物及其组合物和制备方法
TW202227049A (zh) 鹽酸決奈達隆藥物組合物、其製備方法及應用
US20250041425A1 (en) Excipient granulations
CN116687961A (zh) 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法
WO2023034844A1 (en) Delayed release niclosamide formulation
US20210205301A1 (en) Vilazodone inclusion complexes, compositions and preparation thereof
HK40030491A (en) High-strength oral taxane compositions and methods